Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome
Authors
Keywords
-
Journal
JAMA Neurology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2022-05-02
DOI
10.1001/jamaneurol.2022.0829
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome
- (2021) Kim I. Bishop et al. EPILEPSY & BEHAVIOR
- Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth
- (2021) Antonio Gil-Nagel et al. EPILEPSY & BEHAVIOR
- An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies
- (2021) Parthena Martin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome
- (2021) J. Helen Cross et al. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
- Cluster analysis of a large dataset of patients with Lennox-Gastaut syndrome
- (2021) Ali A. Asadi-Pooya et al. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
- Fenfluramine acts as a positive modulator of sigma-1 receptors
- (2020) Parthena Martin et al. EPILEPSY & BEHAVIOR
- Epidemiology, healthcare resource use, and mortality in patients with probable Lennox-Gastaut syndrome: A population-based study on German health insurance data
- (2020) Adam Strzelczyk et al. EPILEPSY & BEHAVIOR
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
- (2019) Lieven Lagae et al. LANCET
- Clinical risk factors in SUDEP
- (2019) Olafur Sveinsson et al. NEUROLOGY
- Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens
- (2019) Rima Nabbout et al. JAMA Neurology
- Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Elizabeth A Thiele et al. LANCET
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
- (2018) Orrin Devinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lennox-Gastaut syndrome: a comprehensive review
- (2017) Ali A. Asadi-Pooya NEUROLOGICAL SCIENCES
- The incidence of SUDEP
- (2017) Olafur Sveinsson et al. NEUROLOGY
- Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
- (2017) Jo Sourbron et al. Frontiers in Pharmacology
- Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations
- (2017) J. Helen Cross et al. Frontiers in Neurology
- Unknown
- (2016) EPILEPSIA
- Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome
- (2011) Y. T. Ng et al. NEUROLOGY
- Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology
- (2008) Alexis Arzimanoglou et al. LANCET NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started